Earned Media GEO Turns AI into Clinical Discovery Tool — Impact on HUTCHMED (China)
- Over 800 million people use AI for answers each week.
- 94% of links cited by AI systems come from non-paid media.
- Credible earned-media placements are crucial for biopharma firms like HUTCHMED (China).
AI-driven media becomes clinical discovery tool for drugmakers
Earned coverage as the backbone of LLM-driven clinical discovery
HCM, a PR agency focused on impact-driven brands, is expanding Generative Engine Optimization (GEO) services that position earned media as the primary source LLMs cite when answering healthcare queries. The firm says more than 800 million people use AI for answers weekly and that 94% of links cited by those AI systems come from non-paid media, a dynamic that makes credible media placements crucial for biopharmaceutical companies such as HUTCHMED (China). The development shifts communications strategy from chasing algorithms to building authoritative narratives that large language models will surface to patients, clinicians and partners.
HCM’s GEO approach fuses traditional media relations with LLM-ready educational explainers and multi-channel syndication, aiming to create the trust signals that drive AI discovery. The agency combines data-driven story ideation, prompt engineering and targeted syndication so that high-credibility coverage is amplified across owned channels, newsletters and social platforms, increasing the chance that models such as ChatGPT, Claude and Gemini reference a company’s materials when responding to queries on disease, trial results or drug safety. CEO Hannah Cranston frames the work as amplifying, not replacing, conventional PR: without clear, widely distributed narratives, she says, AI has little reliable content to reference.
For biopharma firms, the implication is significant: clinical trial results, safety updates and educational materials must be crafted both for human reporters and for LLM ingestion to ensure accurate downstream discovery. GEO is presented as infrastructure that sustains visibility over time, helping companies control the framing of complex scientific outcomes and reducing the risk that AI-driven answers surface incomplete or misleading sources when patients and healthcare professionals seek information.
Early client outcomes illustrate practical gains
HCM cites client cases where educational content and strategic earned placements drive measurable traffic and AI visibility: one client sees a 400% website traffic increase after positioning educational material in response to a major study; a social fitness platform achieves prominent placement in AI-generated recommendations following syndicated coverage in outlets including Business Insider; and a wellness brand secures durable LLM-driven discovery through timely newsjacking and tabloid placement.
GEO’s proprietary methodology compounds authority signals by pairing earned credibility with explainers optimized for LLMs and amplifying them across channels. For companies in the pharmaceutical and healthcare sectors, HCM positions the approach as a strategic investment to protect reputation, improve discovery of clinical information and ensure authoritative sources surface in AI-powered patient and clinician queries.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

